ArticlemAbs2026

Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis.

Gary P Sims et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.